Trials / Completed
CompletedNCT01542385
Primary Reperfusion Secondary Stenting Trial
Immediate vs. Delayed Stenting After Primary Percutaneous Reperfusion in ST Elevation Myocardial Infarction
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 307 (actual)
- Sponsor
- Montreal Heart Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research project is to improve how we treat heart attacks. The study will assess whether it might not be better to wait a few hours before implanting the coronary stent into the coronary artery rather than implanting it immediately, in order to allow the drugs to completely dissolve the clot. This might help to reduce the risks of the clot migrating and damaging the heart. By delaying coronary stent implantation, we hope to be able to reduce the size of the infarction and reduce the risk of suffering from heart failure following a heart attack.
Detailed description
The PRIMACY trial seeks to assess whether a strategy of delayed stent implantation combined with adjunctive anticoagulation is superior to immediate stent implantation at improving cardiovascular outcomes in patients with mechanically reperfused ST-elevation Myocardial Infarction (STEMI). The investigators hypothesize that delayed stent implantation combined with systemic anticoagulation and maximal antiplatelet therapy will reduce the combined occurrence of cardiac death, non-fatal myocardial infarction, congestive heart failure, or unplanned target vessel revascularization over a 9-month period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Stent | Percutaneous coronary intervention: reperfusion with a thrombectomy catheter or a small balloon angioplasty catheter, followed by coronary stenting |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2018-05-01
- Completion
- 2019-08-01
- First posted
- 2012-03-02
- Last updated
- 2020-08-05
Locations
16 sites across 2 countries: Canada, France
Source: ClinicalTrials.gov record NCT01542385. Inclusion in this directory is not an endorsement.